Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- 4 years ago
Hippocratic Post
COVID-19 Update: Chloroquine / Hydroxychloroquine and Azithromycin
Related Post
- Breakthrough paves the way for next generation of vision implants
A group of researchers from Chalmers University of Technology in Sweden, University of Freiburg and…
-
Higher levels of CO2 increase survival of viruses in the air and transmission risk
A new study has revealed for the first time the vital role carbon dioxide (CO2)…
-
Important breakthrough in treating liver disease
New research from the University of Aberdeen could lead to the development of medication for…
Leave a Reply
You must be logged in to post a comment.